JJL reports consulting fees from Genentech, C4 Therapeutics, Blueprint Medicines, Nuvalent, Bayer, Elevation Oncology, Novartis, Mirati Therapeutics, Regeneron, Turning Point Therapeutics, and Pfizer (<US$5000 per year); institutional research funding from Hengrui Therapeutics, Turning Point Therapeutics, Neon Therapeutics, Relay Therapeutics, Bayer, Elevation Oncology, Roche, Linnaeus Therapeutics, Nuvalent, and Novartis; and continuing medical education funding from OncLive, MedStar Health, MLI PeerView, HMP Education, and Northwell Health. JFG has served as a compensated consultant or received honoraria from Bristol Myers Squibb, Genentech/Roche, Takeda, Loxo/Lilly, Blueprint, Gilead, Moderna, AstraZeneca, Curie Therapeutics, Mirati, Nuvalent, Pfizer, Novartis, Merck, iTeos, Karyopharm, Silverback Therapeutics, and GlydeBio; has received research support from Novartis, Genentech/Roche, and Takeda; and institutional research support from Bristol Myers Squibb, Tesaro, Moderna, Blueprint, Jounce, Array Biopharma, Merck, Adaptimmune, Novartis, and Alexo; and has an immediate family member who is an employee with equity at Ironwood Pharmaceuticals.